Skip to main content

Table 3 BPI, BDI and HADS scores throughout the study (mean ± sd) (ES: effect sizes)

From: Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study

 

baseline

week 6

week 12

week 18

week 24

P

BPI mean severity

7.26 ± 1.6

6.69 ± 1.6

6.81 ± 1.8

6.33 ± 2-0

5.97 ± 2.3**

0.0028

ES

 

0.36

0.28

0.58

0.81

 

BPI mean interference with daily activities

8.13 ± 1.6

6.90 ± 2.1**

6.60 ± 2.4***

6.48 ± 2.4***

5.93 ± 2.8***

<0.0001

ES

 

0.77

0.95

1.03

1.38

 

BDI

28.0 ± 11.0

24.9 ± 13.1

21.5 ± 10.4***

19.1 ± 9.9***

19.3 ± 12.1***

<0.0001

ES

 

0.28

0.59

0.81

0.79

 

BDI > 18 (N = 32)

31.2 ± 9.3

27.5 ± 12.7

23.2 ± 10.4***

20.4 ± 10.1***

20.8 ± 12.5***

<0.0001

ES

 

0.40

0.87

1.16

1.12

 

HADS-A

13.9 ± 3.9

13.2 ± 4.5

12.0 ± 4.5*

11.9 ± 4.4**

11.5 ± 5.0**

= 0.0003

ES

 

0.17

0.48

0.52

0.61

 

HADS-A > 7 (N = 37)

14.4 ± 3.4

13.7 ± 4

12.5 ± 4.1*

12.4 ± 4.0*

12.0 ± 4.6**

= 0.0008

ES

 

0.19

0.56

0.60

0.71

 

HADS-D

12.2 ± 4.6

11.5 ± 4.7

10.6 ± 4.7

10.4 ± 5.0*

10.2 ± 4.9*

= 0.0061

ES

 

0.16

0.36

0.41

0.45

 

HADS-D > 7 (N = 34)

13.3 ± 3.7

12.4 ± 4.2

11.2 ± 4.5*

11.0 ± 4.7**

10.7 ± 4.7**

= 0.0007

ES

 

0.25

0.58

0.63

0.71

 
  1. *: p < 0.05, **: p < 0.01 and ***: p < 0.001 in relation to baseline (Tukey's post-test). Bold: large effect sizes.